Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS HCV drug hit by German value assessor

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb's first in class Daklinza (daclatasvir) gives no proven added benefit for hepatitis C patients compared to other therapies, according to the German HTA, IQWiG. The firm has failed to come up with the data needed to prove the drug is better than dual therapy with peginterferon alfa and ribavirin, or triple therapy with peginterferon alfa and ribavirin plus a protease inhibitor (boceprevir or telaprevir), it said.

You may also be interested in...



Brazil Authorizes Oxford/AZ and Sinovac Vaccines

In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.

Success For Dutch Parallel Registration and Reimbursement Pilot

A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.

Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC

The UK’s withdrawal from the EU could upset the Unitary Patent Court project.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel